**Methods** A retrospective review of all patients treated with LTAD (Rocket®) between 2009 and 2019 in Royal Derby Hospital was undertaken and included the indication, frequency of hospital admission for LVP prior to and after LTAD insertion, MELD score, SBP prior to insertion, complications encountered following insertion, the need for re-insertion and duration of the drain.

**Results** 24 (7 female) patients had LTAD inserted under ultrasound guidance by experienced interventional radiologists. Ascites was secondary to liver cirrhosis in 22 patients (NASH 10; ALD 7; HCV 3; HFE 1; PBC 1) and heart failure/cardiomyopathy in 2 patients. The median MELD score was 14 (6–32). Median number of LVP in 6 months prior to LTAD insertion was 5 (0–15), with median interval of 2 weeks. Following LTAD insertion, median LVP in 6 months fell to 0 (0–5). SBP was diagnosed and treated in 7 patients before LTAD insertion, 6 of whom remained on prophylaxis. No immediate complications were reported. Following LTAD, 15 patients (5/15 had pre-LTAD diagnosis) developed SBP at median 60 (20–425) days. Post-LTAD SBP was treated with antibiotics but 5 died. In 10 patients LTAD was removed after median 10 days of antibiotics and only 4 were replaced. For those who had replacement, 2 of 3 patients given prophylaxis suffered recurrent SBP. Other indications for removal were (leak 2; blockage 2). Patients needed hospitalization for median 19 (2–40) days in the 6 months prior to LTAD, and 12 (0–34) days in the following 6 months. In 11 of 20 patients with MELD score less than 21, the drain remained for 90 or more days while the median lifespan of LTAD in the whole cohort was 67 (6–465) days.

**Conclusions** In some patients LTAD achieved long term palliation without hospital admission but many developed SBP post-insertion. Nevertheless there was still a reduction in hospital stay. It was not possible to identify factors which might predict a successful outcome from this small cohort. Further research should focus on the impact of LTAD on quality of life measures, the role of antibiotic prophylaxis and better defining when LTAD is best employed in the natural history of patient’s with ascites.

**Abstract P187 Figure 1** Relation between MELD score and lifespan of drain

**Abstract P187 Table 1**

<table>
<thead>
<tr>
<th>AMA tests</th>
<th>Positive AMA</th>
<th>Positive AMA with cholestasis</th>
<th>Diagnosis of PBC</th>
<th>Treated with UDCA</th>
<th>Adequately dosed UDCA (13–15 mg/kg/day)</th>
<th>Adequate response to UDCA at 12 months (ALP &lt;1.67*ULN)</th>
<th>Referred for second line therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>20783</td>
<td>155</td>
<td>45</td>
<td>29</td>
<td>25/29</td>
<td>23/25</td>
<td>15/19</td>
<td>5</td>
</tr>
</tbody>
</table>
patients who may benefit from second line therapy with OCA. Such cases can be identified through simple audit of UDCA dosing and biochemical response.

REFERENCE

P188 THE PROGNOSTIC VALUE OF THE FRACTIONAL EXCRETION OF UREA IN PATIENTS WITH CIRRHOSIS
Jeremiah Sim*, Christine Toka, Ewan Forrest. Glasgow Royal Infirmary, Glasgow, UK
10.1136/gutjnl-2020-bsgcampus.263

Introduction The development of acute kidney injury (AKI) in cirrhosis is associated with a poor outcome. Patidar et al, 2018 proposed the fractional excretion of urea (FeUrea) to distinguish pre-renal and hepatorenal syndrome from other causes of AKI in cirrhosis. However its prognostic significance out with AKI is unknown.

Aim To assess the associations of FeUrea with liver and renal function and survival in patients with cirrhosis.

Methods Patients with cirrhosis whose urine electrolytes had been assessed in the Gastroenterology wards at Glasgow Royal Infirmary between January 2016 and August 2019 were identified retrospectively. Contemporaneous blood tests were recorded. For outcome assessment the earliest urine electrolyte sample was recorded and subsequent samples within 90 days excluded. Pearson coefficient (r) was calculated for correlation. Cox proportional-hazards regression was used for multivariate analysis of variables related to outcome, and Kaplan-Meier analysis for survival analysis.

Results In total 265 samples were analysed from 157 individuals. FeUrea correlated with markers of inflammation (CRP: r=-0.297; p<0.0001), renal function (creatinine: r=-0.193; p=0.002) and liver function (MELD: r=-0.124; p<0.04). 178 samples were suitable for outcome analysis; 29 (16.2%) had AKI at the time of assessment. 90-day survival was 41.4%, 61.4% and 70.5% for those with FeUrea <21.3%, 21.3–33.4% and >33.4% respectively (p=0.006). On multivariate analysis albumin (p=0.0002), bilirubin (p=0.04), creatinine (p=0.01), FeUrea (p=0.0001) and white cell count (WCC: p=0.02) independently predicted 28-day survival but only FeUrea (p=0.04) and WCC (p=0.02) predicted 90-day survival. MELD and presence of AKI were not independently related to outcome.

Conclusion FeUrea was associated with markers of inflammation and liver dysfunction in patients with cirrhosis. FeUrea was predictive of survival independently of MELD and AKI. The categorisation of patients by FeUrea identified those with a poor 90-day outcome.

P189 ROLE OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) IN TREATING CANCEROUS LESIONS OF THE HEPATOBILIARY SYSTEM
1Saied Froghi*, 2Arjan Singh Sehmbi*, 3Matheus de Andrade, 2Layla Mohammad Hadi, 4Alberto Quaglia, 2Barry Fuller, 5Alberto Quaglia, 2Brian Davidson. 1Royal Free Hospital, London, UK; 2UCL Division of Surgery and Interventional Sciences, London; 3Department of Pathology, Royal Free Hospital, London; 4Department of Surgery and Interventional Sciences UCL, London; 5Department of Mechanical Engineering UCL, London
10.1136/gutjnl-2020-bsgcampus.264

Aims High intensity focused treatment of malignancy (HIFU) is an emerging non-invasive, targeted treatment of malignancy. This review aims to explore the efficacy, safety and optimal technical parameters of HIFU to treat cancerous lesions of the hepatobiliary system.

Methods A systematic search of the English literature was performed until December 2018, interrogating PubMed, Embase and Cochrane Library databases. The following key-words were input in various combinations: ‘HIFU’, ‘High intensity focussed ultrasound’, ‘Hepatobiliary’, ‘Liver’, ‘Cancer’ and ‘Carcinoma’. Extracted content included: Application type, Exposure parameters, Patient demographics, and Treatment outcomes.

Results Twenty-two articles reported on the clinical use of HIFU in 845 individuals to treat cancerous liver lesions. Nineteen series detailed the use of HIFU to treat hepatocellular carcinoma. Mean tumour size was 5.1 cm. Across all studies, HIFU resulted in complete tumour ablation in 51.68%. Data on technical parameters and the procedural structure was very heterogeneous. Eight studies described the use of HIFU alongside other modalities including TACE, RFA and PEI; 58.72% of which resulted in complete tumour ablation. Most common complications were skin burns(17.16%), local pain(5.56%) and fever(1.42%).

Conclusions HIFU is a safe and well-tolerated treatment modality for cancerous lesions of the hepatobiliary system. Combining HIFU with other ablative therapies, particularly TACE, increases the efficacy without increasing complications. Future human clinical studies are required to determine the optimal treatment parameters, better define outcomes and explore the risks and benefits of combination therapies.

P190 PROOF OF CONCEPT & NOVEL TECHNIQUE OF CELL HARVEST USING HISTOTRIPSY: IMPLICATIONS IN CELL TRANSPLANTATION
1Saied Froghi*, 2Matheus De Andrade, 3Layla Mohammad Hadi, 4Alberto Quaglia, 2Barry Fuller, 5Nader Saffari, 2Brian Davidson. 1Royal Free Hospital, London, UK; 2UCL Division of Surgery and Interventional Sciences, London; 3Department of Ultrasonic UCL, London; 4Royal Free Hospital Department of Pathology, London
10.1136/gutjnl-2020-bsgcampus.265

Introduction A potential alternative to liver transplantation is allogenic hepatocyte transplantation, particularly for metabolic disorders. However, some significant hurdles mainly concerned shortage of donor organs, low cell yield as well as lack of long-standing effect needs to be overcome to widen its clinical application. Here we describe an improved technique in cell harvest and isolation.

Methods Pig livers were obtained using organ retrieval techniques and perfused with Soltran solution following a period of cold storage. Perfused livers were subjected to High-Intensity Focused Ultrasound (HIFU), and lesions were incised. Core liquified suspension was sampled and cultured in RPMI cell culture medium. Cell cultures were analysed at 1, 3 and 7 days for viability. H&E staining performed to characterise the lesions.

Results Four different livers were used, and more than 50 lesions created. HIFU created a subcapsular lesion with a core suspension of cells. Adult hepatocytes extracted from core lesion are alive at day 1 and remain alive in culture medium